NASDAQ
TWST

Twist Bioscience Corp

Diagnostics & Research
Healthcare

Prices are adjusted according to historical splits.

Twist Bioscience Corp Stock Price

Vitals

Today's Low:
$22.543
Today's High:
$23.25
Open Price:
$22.83
52W Low:
$11.46
52W High:
$41.87
Prev. Close:
$22.98
Volume:
780133

Company Statistics

Market Cap.:
$1.35 billion
Book Value:
11.462
Revenue TTM:
$235.47 million
Operating Margin TTM:
-92.09%
Gross Profit TTM:
$84.24 million
Profit Margin:
-88.97%
Return on Assets TTM:
-15.14%
Return on Equity TTM:
-28.34%

Company Profile

Twist Bioscience Corp had its IPO on 2018-10-31 under the ticker symbol TWST.

The company operates in the Healthcare sector and Diagnostics & Research industry. Twist Bioscience Corp has a staff strength of 989 employees.

Stock update

Shares of Twist Bioscience Corp opened at $22.83 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $22.54 - $23.25, and closed at $22.99.

This is a +0.04% increase from the previous day's closing price.

A total volume of 780,133 shares were traded at the close of the day’s session.

In the last one week, shares of Twist Bioscience Corp have slipped by -2.42%.

Twist Bioscience Corp's Key Ratios

Twist Bioscience Corp has a market cap of $1.35 billion, indicating a price to book ratio of 1.8983 and a price to sales ratio of 7.0528.

In the last 12-months Twist Bioscience Corp’s revenue was $235.47 million with a gross profit of $84.24 million and an EBITDA of $-191071008. The EBITDA ratio measures Twist Bioscience Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Twist Bioscience Corp’s operating margin was -92.09% while its return on assets stood at -15.14% with a return of equity of -28.34%.

In Q2, Twist Bioscience Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 13.6%.

Twist Bioscience Corp’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-4 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Twist Bioscience Corp’s profitability.

Twist Bioscience Corp stock is trading at a EV to sales ratio of 5.3469 and a EV to EBITDA ratio of -5.1419. Its price to sales ratio in the trailing 12-months stood at 7.0528.

Twist Bioscience Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$810.33 million
Total Liabilities
$72.82 million
Operating Cash Flow
$18.67 million
Capital Expenditure
$4.51 million
Dividend Payout Ratio
0%

Twist Bioscience Corp ended 2024 with $810.33 million in total assets and $0 in total liabilities. Its intangible assets were valued at $810.33 million while shareholder equity stood at $657.55 million.

Twist Bioscience Corp ended 2024 with $0 in deferred long-term liabilities, $72.82 million in other current liabilities, in common stock, $-986791000.00 in retained earnings and $85.81 million in goodwill. Its cash balance stood at $307.46 million and cash and short-term investments were $357.15 million. The company’s total short-term debt was $13,132,000 while long-term debt stood at $0.

Twist Bioscience Corp’s total current assets stands at $445.54 million while long-term investments were $0 and short-term investments were $49.69 million. Its net receivables were $42.58 million compared to accounts payable of $12.18 million and inventory worth $36.35 million.

In 2024, Twist Bioscience Corp's operating cash flow was $18.67 million while its capital expenditure stood at $4.51 million.

Comparatively, Twist Bioscience Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$22.99
52-Week High
$41.87
52-Week Low
$11.46
Analyst Target Price
$25.78

Twist Bioscience Corp stock is currently trading at $22.99 per share. It touched a 52-week high of $41.87 and a 52-week low of $41.87. Analysts tracking the stock have a 12-month average target price of $25.78.

Its 50-day moving average was $22.3 and 200-day moving average was $20.33 The short ratio stood at 12.37 indicating a short percent outstanding of 0%.

Around 158.6% of the company’s stock are held by insiders while 10882% are held by institutions.

Frequently Asked Questions About Twist Bioscience Corp

The stock symbol (also called stock or share ticker) of Twist Bioscience Corp is TWST

The IPO of Twist Bioscience Corp took place on 2018-10-31

Similar Industry Stocks (Diagnostics & Research)

Last Price
Chg
Chg%
$27.75
-0.65
-2.29%
$157.75
-14
-8.15%
$7.02
-0.04
-0.57%
$245.6
-7.3
-2.89%
$34.3
0.97
+2.91%
$267
3
+1.14%
PC Jeweller Limited (PCJEWELLER)
$26.7
-0.91
-3.3%
$25.35
1.2
+4.97%
Shalby Ltd. (540797)
$236.9
-20.6
-8%
$756.2
-40.1
-5.04%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Address

681 Gateway Boulevard, South San Francisco, CA, United States, 94080